Sinopharm Group Co. Ltd.
SHTDY | OTC
$10.31
+$0.14 (+1.38%)
At close: Oct 30, 2026, 3:58 PM ET
$10.31
$0.00 (0.00%)
After-hours:
Oct 30, 2026, 4:00 PM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | 575.17B | 584.51B | 596.57B | 552.15B | 521.05B | 456.41B |
Cost of Revenue | 533.5B | 540.25B | 548.06B | 504.71B | 477B | 416.09B |
Gross Profit | 41.67B | 44.26B | 48.51B | 47.43B | 44.05B | 40.32B |
Operating Income | 16.04B | 16.19B | 20.21B | 20.6B | 19.71B | 17.76B |
Interest Income | 500.25M | 616.97M | 526.21M | 542.77M | 558.56M | 676.36M |
Pretax Income | 14.8B | 14B | 19.51B | 18.56B | 17B | 15.6B |
Net Income | 7.16B | 7.05B | 9.05B | 8.53B | 7.76B | 7.19B |
Selling & General & Admin | 24.02B | 25.57B | 26.15B | 24.9B | 23.2B | 21.19B |
Research & Development | n/a | n/a | n/a | n/a | n/a | n/a |
Other Expenses | 1.61B | 2.49B | 2.15B | 1.93B | 1.14B | 1.37B |
Operating Expenses | 25.63B | 28.07B | 28.3B | 26.83B | 24.34B | 22.56B |
Interest Expense | 2.3B | 2.73B | 2.96B | 3.52B | 3.76B | 3.42B |
Selling & Marketing Expenses | 16.18B | 17.16B | 17.47B | 16.72B | 15.44B | 14.14B |
Cost & Expenses | 559.13B | 568.32B | 576.36B | 528.94B | 499.61B | 436.63B |
Income Tax Expense | 3.97B | 3.58B | 4.5B | 4.22B | 3.94B | 3.5B |
Shares Outstanding (Basic) | 3.12B | 3.12B | 3.12B | 3.12B | 3.11B | 3.11B |
Shares Outstanding (Diluted) | 3.12B | 3.12B | 3.12B | 3.12B | 3.11B | 3.11B |
EPS (Basic) | 2.29 | 2.26 | 2.90 | 2.73 | 2.49 | 2.31 |
EPS (Diluted) | 2.29 | 2.26 | 2.90 | 2.73 | 2.49 | 2.31 |
EBITDA | 19.26B | 20.17B | 26.9B | 26.25B | 24.68B | 22.62B |
EBIT | 17.23B | 17.82B | 22.47B | 22.08B | 20.76B | 19.02B |
Depreciation & Amortization | 2.03B | 2.36B | 4.43B | 4.17B | 3.92B | 3.6B |
Add to Watchlist
Select watchlists to add or remove SHTDY